Search
Jun 12, 2024
One Milestone at Harvard Enterprise Research Campus with Breakthrough Properties' CEO Dan Belldegrun
At an event at Harvard's School of Engineering and Applied Sciences today, Dan Belldegrun describes the future of the Harvard Enterprise...
Jun 11, 2024
The CEO of Syntis Bio describes a novel obesity program that entered the clinic today and a broader platform that leverages the small intestine to impact metabolism and drug absorption
Rahul Dhanda describes the technology that Syntis uses to coat the upper region of the small intestine to modulate nutrient uptake, and...
Jun 11, 2024
Marengo Therapeutics' CEO Zhen Su on the expansion of a partnership with Ipsen to activate T-cells against cold tumors
After announcing a partnership expansion with Ipsen on Friday, Zhen Su describes how to succeed against cold tumors where T-cells are not...
Jun 10, 2024
Longboard Pharma's CEO describes today's open label extension data for bexicaserin in Developmental and Epileptic Encephalopathies
Kevin Lind explains how patients randomized to therapy and placebo crossover patients are seeing comparable reductions in seizure levels....
Jun 10, 2024
Replimune's CEO discusses last week's PD-1 refractory melanoma data and the company's plans to file for accelerated approval
Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from...
Jun 10, 2024
University of Pennsylvania undergraduate students founded a biotech company that is working on bioengineered plants as an alternative to horseshoe crab blood for pharmaceutical endotoxin testing
Co-Founder Aravind Krishnan describes the scientific idea behind ToxiSense, and how the Philadelphia-based Science Center's Founders...
Jun 7, 2024
X4 Pharma's CEO on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications
Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4...
Jun 7, 2024
The CEO of Arcturus on data presented today for an inhaled mRNA therapy at the 47th European Cystic Fibrosis Conference
Joseph Payne describes data from the first four patients with CF to receive this inhaled mRNA at #ECFS2024. He also summarizes Arcturus'...
Jun 6, 2024
The CEO of Rejuvenate Bio on the company's liver directed gene therapy program targeting FGF21
Daniel Oliver describes how Rejuvenate believes this program could have utility against arrhythmias and heart failure in both humans and...
Jun 6, 2024
Mizuho senior analyst Salim Syed joins BiotechTV for Analyst Thursdays from the New York Stock Exchange
Salim Syed gives his take on Cytokinetics, BridgeBio, Enliven, Vaxcyte, and Wave Life Sciences.
Jun 6, 2024
Insmed's CEO on the success of brensocatib in bronchiectasis and what it means for the company
Will Lewis describes last week's data and what means not just for bronchiectasis but also as a broader proof of concept for DPP1...
Jun 6, 2024
The CEO of FibroBiologics describes the idea of using fibroblasts rather than stem cells for regenerative medicine and chronic diseases
Pete O'Heeron makes the case for fibroblasts and describes FibroBiologics's clincal MS program and upcoming ones for diabetic wound care...
Jun 6, 2024
Biohaven's CEO recaps last week's R&D Day and walks us through the company's pipeline
From the NYSE, Vlad Coric covers programs including protein degradation, ADCs, myostatin inhibition, the ion channel programs, and...
Jun 5, 2024
Ali Gorman and Brad Loncar review #ASCO24 key highlights
We summarize BiotechTV's coverage of the conference including Enhertu, bispecific antibodies, the Summit news, and Moderna's highly...
Jun 5, 2024
The CEO of YourChoice Therapeutics describes developing a birth control solution for men
Akash Bakshi explains how YourChoice is leveraging learnings about how men who are vitamin A deficient are infertile or subfertile to...
Jun 5, 2024
Backed by the sovereign wealth fund of Abu Dhabi, Mubadala Capital's executive director describes its investment strategy in life sciences
Alaa Halawa introduces us to Mubadala Capital, describes what type of investments it looks for, and gives his take on the current...
Jun 4, 2024
The head of Leaps by Bayer describes this program and how it helps Bayer be at the forefront of innovation
Juergen Eckhardt describes how this strategic impact investing arm works within Bayer, the types of investments they look for and have...
Jun 4, 2024
Allucent at ASCO 2024
From McCormick Place during #ASCO24, we talk with Brian Abbott, MD, Allucent's Global Head of Oncology, about the latest trends in...
Jun 3, 2024
Moderna CEO Stéphane Bancel walks us through Moderna and Merck's 3-year individual neoantigen therapy + Keytruda adjuvant melanoma data at #ASCO24 and Moderna's broader oncology pipeline
At Moderna's analyst meeting at #ASCO24 in Chicago, Stéphane Bancel shows the Kaplan-Meier curve separation over time for the neoantigen...
Jun 3, 2024
Rachel Haurwitz on Caribou's #ASCO24 data and the rationale for taking time to look further at HLA matching for allo CAR-T
Rachel Haurwitz elaborates on the data update for CB-010 that was presented at ASCO and describes why the company will push back the...
.png){kind=logo}
